 SOUTH SAN FRANCISCO, Calif., June 13, 2021 GLOBE NEWSWIRE -- RAPT Therapeutics, Inc. Nasdaq: RAPT, a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases, today announced that the Company plans to report top line data from its Phase 1b clinical trial of RPT193 in patients with moderate to severe atopic dermatitis AD in a premarket press release and webcast on Monday, June 14, 2021. 